Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial
China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...
Gene therapy
Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems
Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot...
Frontera Therapeutics’ Gene Therapy FT-017 Gains Clinical Trial Approvals for HCM
Sino-US biotech company Frontera Therapeutics, Inc. announced that its recombinant adeno-associated virus (rAAV) gene therapy...
Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...
Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy
China-based Gene Cradle has received approval from the National Medical Products Administration (NMPA) to proceed...
Salubris Pharma’s YOLT-101 Gene Editing Drug Accepted for NMPA Review
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that the National Medical Products Administration...
AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients
Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...
Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy
China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...
HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy
Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc.,...
Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...
SineuGene Therapeutics’ SNUG01 Receives FDA Clearance for ALS Clinical Study
Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced last week that...
AccurEdit Therapeutics Receives FDA Orphan Drug Designation for ATTR Treatment
China-based AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Orphan Drug Designation (ODD) from the US...
Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
Sino-US firm Frontera Therapeutics, Inc. announced receiving approval from China’s National Medical Products Administration (NMPA)...
Cell Store and Cygenta Forge Strategic Alliance in Cell and Gene Therapy Field
Beijing-based biotech firms Cell Store, a biological sample cryopreservation technology platform, and Cygenta, a Contract...
YolTech Therapeutics’ YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 Trial
YolTech Therapeutics, a Shanghai-based startup specializing in lipid nanoparticle delivery and gene editing, announced positive...
Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...
Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies
Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance...
Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931
German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...
Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease
German pharmaceutical giant Bayer (ETR: BAYN) announced that its gene therapy subsidiary AskBio Inc. has...
Boehringer Ingelheim Partners with ExpressionEdits on Gene Therapy Tech
German pharmaceutical giant Boehringer Ingelheim has entered into a collaboration and licensing agreement with UK-based...